Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Boston, Massachusetts, United States1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-09 | NCT06854653 |